Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05730036
Title A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidomide and Dexamethasone (EPd) Combination, in Participants With Relapsed/Refractory Multiple Myeloma (LINKER-MM3)
Acronym LINKER-MM3
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Regeneron Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | POL | NLD | ITA | ISR | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS


No variant requirements are available.